Advanced OCT Analysis of Biopsy-proven Vitreoretinal Lymphoma.
Journal
American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
10
08
2021
revised:
17
11
2021
accepted:
18
11
2021
pubmed:
30
11
2021
medline:
31
5
2022
entrez:
29
11
2021
Statut:
ppublish
Résumé
Although diagnosing vitreoretinal lymphoma (VRL) can be challenging, early detection is critical for visual prognosis. We analyzed the spectrum of optical coherence tomography (OCT) findings in patients with biopsy-proven VRL and correlate these features with clinical parameters. This retrospective cross-sectional study was a multicenter chart review from 13 retina, uveitis, and ocular oncology clinics worldwide from 2008 to 2019. We included patients with a diagnosis of biopsy-proven VRL imaged with OCT at presentation. Ocular information, systemic information, and multimodal retinal imaging findings were collected and studied. The main outcome measure was the characteristics of VRL on OCT. A total of 182 eyes of 115 patients (63 women, mean age 65 years) were included in this study. The disease was bilateral in 81 patients (70%), and mean baseline visual acuity was 0.2 ± 0.89 logMAR (Snellen equivalent, 20/32). At baseline, 38 patients (33%) presented with isolated ocular involvement, 54 (45%) with associated central nervous system involvement, and 11 (10%) with other systemic lymphomatous involvement; an additional 12 patients (10%) presented with central nervous system and other systemic involvement. On OCT, tumor infiltration was identified in various retinal layers, including lesions in the subretinal pigment epithelium compartment (91% of eyes), the subretinal compartment (43% of eyes), and the intraretinal compartment (7% of eyes). OCT analysis of eyes with VRL identified 3 main regions of retinal infiltration. Subretinal pigment epithelium location, with or without subretinal infiltration, was the most common pattern of involvement and isolated intraretinal infiltration was the least.
Identifiants
pubmed: 34843686
pii: S0002-9394(21)00620-6
doi: 10.1016/j.ajo.2021.11.023
pmc: PMC9639626
mid: NIHMS1830058
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16-26Subventions
Organisme : Medical Research Council
ID : MR/T019050/1
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Références
Clin Exp Ophthalmol. 2008 Aug;36(6):564-78
pubmed: 18954321
Ophthalmology. 2003 Feb;110(2):421-6
pubmed: 12578791
Graefes Arch Clin Exp Ophthalmol. 2004 Nov;242(11):901-13
pubmed: 15565454
Ophthalmology. 2001 Feb;108(2):386-99
pubmed: 11158819
Ocul Immunol Inflamm. 2009 Jul-Aug;17(4):227-37
pubmed: 19657975
Trans Am Ophthalmol Soc. 2012 Dec;110:117-29
pubmed: 23818738
Pathologe. 2017 Nov;38(6):515-520
pubmed: 28993856
Retina. 2002 Feb;22(1):37-43
pubmed: 11884876
Jpn J Ophthalmol. 2012 Jul;56(4):383-9
pubmed: 22661396
Ophthalmic Surg Lasers Imaging. 2011 Sep 29;42 Online:e97-9
pubmed: 21956854
Ocul Immunol Inflamm. 2009 Mar-Apr;17(2):69-72
pubmed: 19412864
Retina. 2020 Feb;40(2):391-398
pubmed: 31972811
Ophthalmol Retina. 2021 Feb;5(2):105-107
pubmed: 33549199
Retin Cases Brief Rep. 2014 Fall;8(4):314-7
pubmed: 25372536
Br J Ophthalmol. 1997 Jan;81(1):31-6
pubmed: 9135405
J Neurosurg. 1988 Jun;68(6):835-53
pubmed: 3286832
Blood. 2015 Jul 2;126(1):76-9
pubmed: 25900979
Cancer Control. 2004 Sep-Oct;11(5):285-95
pubmed: 15377987
J Neuropathol Exp Neurol. 2014 Jun;73(6):478-94
pubmed: 24806301
Ann Oncol. 2007 Nov;18(11):1851-5
pubmed: 17804469
Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):412-7
pubmed: 22995952
J Ophthalmic Inflamm Infect. 2011 Dec;1(4):171
pubmed: 21822590
Graefes Arch Clin Exp Ophthalmol. 2016 Dec;254(12):2319-2326
pubmed: 27251192
Int Ophthalmol. 2018 Feb;38(1):353-361
pubmed: 28039672
Retina. 2011 Mar;31(3):435-40
pubmed: 21336066
Br J Ophthalmol. 2021 Oct;105(10):1415-1420
pubmed: 32920528
Ocul Immunol Inflamm. 2000 Dec;8(4):243-50
pubmed: 11262654
Eye (Lond). 2013 Feb;27(2):153-62
pubmed: 23196650
Semin Ophthalmol. 2006 Jul-Sep;21(3):125-33
pubmed: 16912010
Recent Results Cancer Res. 1994;135:155-69
pubmed: 8047690
Am J Ophthalmol. 2014 Mar;157(3):526-31
pubmed: 24211361
Am J Ophthalmol. 2014 Dec;158(6):1253-1261.e2
pubmed: 25174893
Cancer. 1993 Aug 1;72(3):843-9
pubmed: 8334638
Retina. 2014 Feb;34(2):366-72
pubmed: 23958842
Surv Ophthalmol. 2014 Sep-Oct;59(5):503-16
pubmed: 24560125
Br J Ophthalmol. 2018 Oct;102(10):1362-1366
pubmed: 29306864
Discov Med. 2013 Feb;15(81):93-100
pubmed: 23449111
Retina. 2021 Feb 1;41(2):249-258
pubmed: 32349103
Neurology. 2008 Oct 21;71(17):1355-60
pubmed: 18936428
BMC Ophthalmol. 2016 Jul 08;16:103
pubmed: 27391815
Am J Ophthalmol Case Rep. 2020 Apr 08;18:100696
pubmed: 32322750
JAMA Ophthalmol. 2019 Feb 1;137(2):194-198
pubmed: 30489610
Ocul Immunol Inflamm. 2020;28(1):147-155
pubmed: 30335535
Oncologist. 2011;16(11):1589-99
pubmed: 22045784
Ophthalmology. 1993 Sep;100(9):1399-406
pubmed: 8371930
Ocul Oncol Pathol. 2016 Oct;2(4):242-245
pubmed: 27843904
Am J Ophthalmol. 2009 May;147(5):886-94, 894.e1
pubmed: 19243734